Ovarian carcinomatosis: How the radiologist can help plan the surgical approach

Radiographics

Volumn 32, Issue 6, 2012, Pages 1775-1800

  Nougaret, Stephanie ^a   Addley, Helen C ^b   Colombo, Pierre Emmanuel ^c   Fujii, Shinya ^d   Al Sharif, Shaza S ^a   Tirumani, Sree Harsha ^a,f   Jardon, Kris ^e   Sala, Evis ^b,g   Reinhold, Caroline ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c CENTRE VAL D AURELLE   (France)

^d TOTTORI UNIVERSITY   (Japan)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOMA; DIAGNOSTIC IMAGING; FEMALE; HUMAN; METASTASIS; OVARY TUMOR; PATHOLOGY; PATIENT CARE PLANNING; PERITONEUM TUMOR; TUMOR SEEDING;

CARCINOMA; CHEMOTHERAPY, ADJUVANT; DIAGNOSTIC IMAGING; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM SEEDING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATIENT CARE PLANNING; PERITONEAL NEOPLASMS;

EID: 84867586468     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.326125511     Document Type: Article

References (75)

1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009;472:413-437.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59 (4):225-249.
3. Averette HE, Donato DM. Ovarian carcinoma: advances in diagnosis, staging, and treatment. Cancer 1990;65(3 suppl):703-708.
4. Wagner BJ, Buck JL, Seidman JD, McCabe KM. Ovarian epithelial neoplasms: radiologic-pathologic correlation. RadioGraphics 1994;14(6):1351-1374.
5. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376(9747):1155-1163.
6. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10): 943-953.
7. Meyers MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 1973;119(1):198-206.
8. Coakley FV, Hricak H. Imaging of peritoneal and mesenteric disease: key concepts for the clinical radiologist. Clin Radiol 1999;54(9):563-574.
9. Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol 1974;119(7):991-994.
10. Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer: an autopsy study. Cancer 1989;64(7):1508-1513.
11. Walkey MM, Friedman AC, Sohotra P, Radecki PD. CT manifestations of peritoneal carcinomatosis. AJR Am J Roentgenol 1988;150(5):1035-1041.
12. Low RN. MR imaging of the peritoneal spread of malignancy. Abdom Imaging 2007;32(3):267-283.
13. Arai K, Makino H, Morioka T, et al. Enhancement of ascites on MRI following intravenous administration of Gd-DTPA. J Comput Assist Tomogr 1993;17(4):617-622.
14. Low RN, Sigeti JS. MR imaging of peritoneal disease: comparison of contrast-enhanced fast multiplanar spoiled gradient-recalled and spin-echo imaging. AJR Am J Roentgenol 1994;163(5):1131-1140.
15. Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204(2):513-520.
16. Pannu HK, Bristow RE, Montz FJ, Fishman EK. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. RadioGraphics 2003;23(3):687-701.
17. Fujii S, Matsusue E, Kanasaki Y, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 2008;18(1):18-23.
18. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings-a feasibility study. AJR Am J Roentgenol 2009;193(2):461-470.
19. Mitchell DG, Hill MC, Hill S, Zaloudek C. Serous carcinoma of the ovary: CT identification of metastatic calcified implants. Radiology 1986;158(3): 649-652.
20. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001;82(3):489-497.
21. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006; 107(1):77-85.
22. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43.
23. Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009;35(2):135-143.
24. Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol Oncol 2009;112(1):16-21.
25. Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003;197(6):955-963.
26. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005;96(2):301-306.
27. Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL. Ovarian cancer: staging with CT and MR imaging. Radiology 1995;197 (3):619-626.
28. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000;215(3):761-767.
29. Steinberg JJ, Demopoulos RI, Bigelow B. The evaluation of the omentum in ovarian cancer. Gynecol Oncol 1986;24(3):327-330.
30. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 2002;223 (2):495-499.
31. de Bree E, Koops W, Kröger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004;86(2):64-73.
32. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003;12(3):703-727, xiii.
33. Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 2010;101(8):713-724.
34. Chen SS, Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 1983;16(1):95-100.
35. Tangjitgamol S, Manusirivithaya S, Sheanakul C, et al. Can we rely on the size of the lymph node in determining nodal metastasis in ovarian carcinoma? Int J Gynecol Cancer 2003;13(3):297-302.
36. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials-by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115(6):1234-1244.
37. Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 2003;13(5):943-949.
38. Kolev V, Mironov S, Mironov O, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. Int J Gynecol Cancer 2010;20(6):979-984.
39. Holloway BJ, Gore ME, A'Hern RP, Parsons C. The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol 1997;52(9):692-697.
40. Akin O, Sala E, Moskowitz CS, et al. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. Radiology 2008;248(2):511-517.
41. Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Beecham JB, Bonfiglio TA. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Pathol 1988;19(11):1273-1279.
42. Dvoretsky PM, Richards KA, Angel C, et al. Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 1988;19(1):57-63.
43. Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 2008;33(1):87-93.
44. Low RN, Semelka RC, Worawattanakul S, Alzate GD. Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT in 164 patients. J Magn Reson Imaging 2000;12(2):269-277.
45. Forstner R, Sala E, Kinkel K, Spencer JA; European Society of Urogenital Radiology. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 2010;20(12):2773-2780.
46. Brun JL, Rouzier R, Selle F, Houry S, Uzan S, Daraï E. Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. BMC Cancer 2009;9:171.
47. Rutten MJ, Gaarenstroom KN, Van Gorp T, et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. BMC Cancer 2012;12(1):31.
48. Fagotti A, Fanfani F, Vizzielli G, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol 2010;116(1):72-77.
49. Javitt MC. ACR Appropriateness Criteria on staging and follow-up of ovarian cancer. J Am Coll Radiol 2007;4(9):586-589.
50. Low RN, Semelka RC, Worawattanakul S, Alzate GD, Sigeti JS. Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT, with subsequent surgical correlation. Radiology 1999;210(3):625-632.
51. Kyriazi S, Collins DJ, Morgan VA, Giles SL, deSouza NM. Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. RadioGraphics 2010;30(5):1269-1285.
52. Bozkurt M, Doganay S, Kantarci M, et al. Comparison of peritoneal tumor imaging using conventional MR imaging and diffusion-weighted MR imaging with different b values. Eur J Radiol 2011; 80(2):224-228.
53. 1F]FDG-PET/CT. Abdom Imaging 2010;35(6):701-707.
54. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009;71(1):164-174.
55. Yoshida Y, Kurokawa T, Kawahara K, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004;182 (1):227-233.
56. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14(5):1545-1551.
57. Tuxen MK, Sölétormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21(3):215-245.
58. Folk JJ, Botsford M, Musa AG. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol 1995;57(2):178-182.
59. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
60. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6(8):583-592.
61. Venkatasubramanian R, Henson MA, Forbes NS. Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J Theor Biol 2008;253(1): 98-117.
62. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009;35(4):309-321.
63. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S-150S.
64. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23(30):7445-7453.
65. Martoni AA, Fanti S, Zamagni C, et al. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. Q J Nucl Med Mol Imaging 2011;55(1):81-90.
66. Sala E, Priest AN, Kataoka M, et al. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla-technical development. Eur Radiol 2010;20(2):491-496.
67. Sala E, Kataoka MY, Priest AN, et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response-and metastasis-specific effects. Radiology 2012;263(1):149-159.
68. Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology 2011;261(1):182-192.
69. Zahra MA, Tan LT, Priest AN, et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 2009;74(3):766-773.
70. Priest AN, Gill AB, Kataoka M, et al. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med 2010;63(4):1044-1049.
71. Lassau N, Chebil M, Chami L, Bidault S, Girard E, Roche A. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target Oncol 2010;5(1):53-58.
72. Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification-preliminary results. Radiology 2011;258(1):291-300.
73. Forstner R, Hricak H, Powell CB, Azizi L, Frankel SB, Stern JL. Ovarian cancer recurrence: value of MR imaging. Radiology 1995;196(3):715-720.
74. Kurtz AB, Tsimikas JV, Tempany CM, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis-report of the Radiology Diagnostic Oncology Group. Radiology 1999;212(1):19-27.
75. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-125.